Manufacturer
PFIZER PHARMACEUTICALS LLC
Contents
Eplerenone
Indication
Reduce risk of CV mortality & morbidity in stable patients w/ left ventricular dysfunction & clinical evidence of heart failure after recent MI.
Instruction
May be taken with or without food.
Drug interaction
Potentiation of antihypertensive & diuretic effects w/ K-sparing diuretics & K supplements. Increased risk of hyperkalemia w/ ACE inhibitors, ARBs; cyclosporin, tacrolimus; trimethoprim. Monitor lithium plasma conc. May lead to acute renal failure w/ NSAIDs. Potential increased hypotensive effect &/or postural hypotension by α1-blockers. Increased antihypertensive effects w/ TCAs, neuroleptics, amifostine, baclofen. Decreased antihypertensive effect w/ glucocorticoids, tetracosactide. Increased AUC of digoxin. Increased AUC by mild to moderate & strong CYP3A4 inhibitors. Decreased AUC by strong CYP3A4 inducers.
Malaysia
